BCR-ABL-IN-1 is primarily used in research settings to study its inhibitory effects on the BCR-ABL fusion protein, which is associated with chronic myeloid leukemia (CML). It serves as a tool compound to investigate the mechanisms of BCR-ABL-driven oncogenesis and to explore potential therapeutic strategies for CML. Researchers utilize it to evaluate its efficacy in blocking the tyrosine kinase activity of BCR-ABL, which is crucial for the proliferation of leukemia cells. Additionally, it aids in understanding resistance mechanisms to existing BCR-ABL inhibitors and in developing next-generation targeted therapies. Its application extends to preclinical studies, where it helps assess pharmacokinetics, pharmacodynamics, and safety profiles in cellular and animal models.